BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
72.01
+0.29 (0.40%)
At close: Nov 28, 2025, 1:00 PM EST
72.49
+0.48 (0.67%)
After-hours: Nov 28, 2025, 4:51 PM EST
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $120.70M in the quarter ending September 30, 2025, with 4,318.01% growth. This brings the company's revenue in the last twelve months to $353.78M, up 62.46% year-over-year. In the year 2024, BridgeBio Pharma had annual revenue of $221.90M with 2,285.27% growth.
Revenue (ttm)
$353.78M
Revenue Growth
+62.46%
P/S Ratio
38.78
Revenue / Employee
$484,630
Employees
730
Market Cap
13.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BBIO News
- 4 days ago - BridgeBio to Participate in December Investor Conferences - GlobeNewsWire
- 6 days ago - BridgeBio Pharma: Set For New Commercial Launches After Trial Successes - Seeking Alpha
- 9 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 21 days ago - Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations - GlobeNewsWire
- 22 days ago - National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry - GlobeNewsWire
- 25 days ago - BridgeBio to Participate in November Investor Conferences - GlobeNewsWire
- 26 days ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch